1: Raether W, Hänel H. Rilopirox--a new hydroxypyridone antifungal with fungicidal properties. Mycoses. 1990 Apr;33(4):191-202. PubMed PMID: 2233892.
2: Nenoff P, Haustein UF. In vitro susceptibility testing of Malassezia furfur against rilopirox. Skin Pharmacol. 1997;10(5-6):275-80. PubMed PMID: 9449166.
3: Hrabé de Angelis M, Dannhorn DR, Hänel H, Kirchner C. Effects of rilopirox on rabbit blastocysts in a protein-free in vitro culture under different culture conditions. Arzneimittelforschung. 1994 May;44(5):674-8. PubMed PMID: 8024647.
4: Braga PC, Maci S, Dal Sasso M, Piatti G, Bohn M. Alterations in surface morphology of Candida albicans produced by rilopirox: a scanning electron microscopy study. J Chemother. 1995 Dec;7(6):519-24. PubMed PMID: 8667036.
5: Nenoff P, Taneva E, Pfeil B, Oswald U, Haustein UF. In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant Candida isolates from patients with HIV infection. Mycoses. 1999 Apr;42(1-2):55-60. PubMed PMID: 10394849.
6: Kruse R, Hengstenberg W, Hänel H, Raether W. Studies for the elucidation of the mode of action of the antimycotic hydroxypyridone compound, rilopirox. Pharmacology. 1991;43(5):247-55. PubMed PMID: 1664523.
7: Braga PC, Dal Sasso M, Maci S, Piatti G, Dannhorn DR, Bohn M. Inhibition of Candida albicans adhesiveness to human buccal and vaginal cells by sub-inhibitory concentrations of rilopirox. Arzneimittelforschung. 1995 Jan;45(1):84-7. PubMed PMID: 7893277.
8: Reitze HK, Dannhorn DR, Hänel H, Seitz KA. Ultrastructural investigations of Candida albicans after in vitro treatment with the new fungicidal agent rilopirox. Mycoses. 1993 Nov-Dec;36(11-12):385-95. PubMed PMID: 7935570.
9: Sigle HC, Schäfer-Korting M, Korting HC, Hube B, Niewerth M. In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses. 2006 May;49(3):159-68. PubMed PMID: 16681805.
10: Harada I, Mitsui K, Uchida K, Yamaguchi H. [The in vitro properties of a new hydroxypyridone antimycotic rilopirox, with special reference to its anti-Candida activity]. Jpn J Antibiot. 1999 Feb;52(2):146-52. Japanese. PubMed PMID: 10221179.
11: Braga PC, Maci S, Dal Sasso M, Bohn M. Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Chemotherapy. 1996 Jul-Aug;42(4):259-65. PubMed PMID: 8804793.
12: Harada I, Mitsui K, Uchida K, Yamaguchi H. [In vitro antifungal activity of rilopirox, a new hydroxypyridone antimycotic agent]. Jpn J Antibiot. 1997 Feb;50(2):195-9. Japanese. PubMed PMID: 9100079.
13: Rubin AI, Bagheri B, Scher RK. Six novel antimycotics. Am J Clin Dermatol. 2002;3(2):71-81. Review. PubMed PMID: 11893219.
14: Korting HC, Grundmann-Kollmann M. The hydroxypyridones: a class of antimycotics of its own. Mycoses. 1997 Nov;40(7-8):243-7. Review. PubMed PMID: 9476505.
15: Hänel H, Smith-Kurtz E, Pastowsky S. [Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect]. Mycoses. 1991;34 Suppl 1:91-3. German. PubMed PMID: 1840158.
16: Torres-Rodríguez JM. New topical antifungal drugs. Arch Med Res. 1993 Winter;24(4):371-5. Review. PubMed PMID: 8118161.
17: Nenoff P, Reinl P, Haustein UF. [The yeast fungus Malassezia: pathogen, pathogenesis and therapy]. Hautarzt. 2001 Jan;52(1):73-86. Review. German. PubMed PMID: 11220247.